Clinigen, the global pathfinder accelerating patient access to critical medicines across the lifecycle, confirms the close of its acquisition of SSI Strategy, a trusted strategic consulting partner to biotech innovators. The completion of this transaction brings together SSI’s renowned strategic advisory depth, established U.S. and European footprint, and pioneering partnership models with Clinigen’s global operational reach and decades of experience in clinical trial supply, managed access, and commercialisation. The deal adds the specialised capabilities of over 200 employees, including 145 expert consultants, spanning Medical, Clinical, and Regulatory competencies, and a deep client base of over 280 biopharma companies.
Read the full article: Clinigen Finalises Acquisition of SSI Strategy //
Source: https://www.clinigengroup.com/news/news-container/2025/clinigen-finalises-acquisition-of-ssi-strategy/